Details

Genetic variability in the glucocorticoid pathway and treatment outcomes in hospitalized patients with COVID-19 : a pilot study
ID Štampar, Patricija (Author), ID Blagus, Tanja (Author), ID Goričar, Katja (Author), ID Bogovič, Petra (Author), ID Turel, Gabriele (Author), ID Strle, Franc (Author), ID Dolžan, Vita (Author)

.pdfPDF - Presentation file, Download (725,84 KB)
MD5: 3D6763033BF52AEE3790C94E399E5FA4
URLURL - Source URL, Visit https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1418567/full This link opens in a new window

Abstract
Introduction: Corticosteroids are widely used for the treatment of coronavirus disease (COVID)-19. Genetic polymorphisms of the glucocorticoid receptor, metabolizing enzymes, or transporters may affect treatment response to dexamethasone. This study aimed to evaluate the association of the glucocorticoid pathway polymorphisms with the treatment response and short-term outcomes in patients with severe COVID-19. Methods: Our pilot study included 107 hospitalized patients with COVID-19 treated with dexamethasone and/or methylprednisolone, genotyped for 14 polymorphisms in the glucocorticoid pathway. Results: In total, 83% of patients had severe disease, 15.1% had critical disease and only 1.9% had moderate disease. CYP3A4 rs35599367 was the major genetic determinant of COVID-19 severity as carriers of this polymorphism had higher risk of critical disease (OR = 6.538; 95% confidence interval = 1.19–35.914: p = 0.031) and needed intensive care unit treatment more frequently (OR = 10; 95% CI = 1.754–57.021: p = 0.01). This polymorphism was also associated with worse disease outcomes, as those patients had to switch from dexamethasone to methylprednisolone more often (OR = 6.609; 95% CI = 1.137–38.424: p = 0.036), had longer hospitalization (p = 0.022) and needed longer oxygen supplementation (p = 0.040). Carriers of NR3C1 rs6198 polymorphic allele required shorter dexamethasone treatment (p = 0.043), but had higher odds for switching therapy with methylprednisolone (OR = 2.711; 95% CI = 1.018–7.22: p = 0.046). Furthermore, rs6198 was also associated with longer duration of hospitalization (p = 0.001) and longer oxygen supplementation (p = 0.001). NR3C1 rs33388 polymorphic allele was associated with shorter hospitalization (p = 0.025) and lower odds for ICU treatment (OR = 0.144; 95% CI = 0.027–0.769: p = 0.023). GSTP1 rs1695 was associated with duration of hospitalization (p = 0.015), oxygen supplementation and (p = 0.047) dexamethasone treatment (p = 0.022). Conclusion: Our pathway-based approach enabled us to identify novel candidate polymorphisms that can be used as predictive biomarkers associated with response to glucocorticoid treatment in COVID-19. This could contribute to the patient's stratification and personalized treatment approach.

Language:English
Keywords:COVID-19, dexamethasone, glucocorticoid pathway, methylprednisolone, polymorphism, treatment outcome
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2024
Number of pages:17 str.
Numbering:Vol. 15, art. 1418567
PID:20.500.12556/RUL-166841 This link opens in a new window
UDC:577.2:615
ISSN on article:1663-9812
DOI:10.3389/fphar.2024.1418567 This link opens in a new window
COBISS.SI-ID:206252291 This link opens in a new window
Publication date in RUL:27.01.2025
Views:447
Downloads:101
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Frontiers in pharmacology
Shortened title:Front Pharmacol
Publisher:Frontiers Media
ISSN:1663-9812
COBISS.SI-ID:29551833 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:COVID-19, deksametazon, glukokortikoidna pot, metilprednizolon, polimorfizem, izid zdravljenja

Projects

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P1-0170
Name:Molekulski mehanizmi uravnavanja celičnih procesov v povezavi z nekaterimi boleznimi pri človeku

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P3-0296
Name:Bolezni in povzročitelji, ki jih v Sloveniji prenašajo členonožci

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back